Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (Zhujiang Hospital)
- Development stage
- Unknown
- Lead developer
- Southern Medical University Zhujiang Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T cells (Zhujiang Hospital) is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy developed by Zhujiang Hospital. The treatment involves the genetic modification of a patient's T cells to express a CAR that specifically targets the CD19 antigen, a protein consistently expressed on B-lineage cells. Once re-infused, these engineered T cells recognize and eliminate CD19-positive malignant cells. This specific program is being evaluated as a consolidation therapy for adolescent and adult patients with acute B-lymphoblastic leukemia (B-ALL) who are in remission but cannot undergo allogeneic hematopoietic stem cell transplantation due to factors such as age, comorbidities, or lack of a suitable donor.
- Other names
- CD19 CAR-T cells injectionCD-19 CAR-T cells injectionCD 19 CAR-T cells injectionCD19-directed CAR-T cell therapyCD-19-directed CAR-T cell therapyCD 19-directed CAR-T cell therapyCD19 CAR-T Consolidation in B-ALLCD-19 CAR-T Consolidation in B-ALLCD 19 CAR-T Consolidation in B-ALL
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T cells (Zhujiang Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (Zhujiang Hospital).